Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16047072 | 0.84 | SMN1; SMN2 (0.39) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL14027048 | 0.83 | PIM1 (0.42) | ESR2POLBRECQLALDH1A1MAPT | |
| SCHEMBL642695 | 0.83 | GAA (0.44) | ESR2CA12CA2CA7CA9 | |
| SCHEMBL12035848 | 0.83 | MAOB (0.45) | ESR2POLBRECQLALDH1A1MAPT | |
| SCHEMBL9923380 | 0.81 | CA12 (0.41) | ESR2CA12CA2CA7CA9 | |
| SCHEMBL16047195 | 0.80 | SLC22A12 (0.59) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL29784522 | 0.79 | ESR2 (0.46) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL27185513 | 0.79 | ESR2 (0.46) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL4682666 | 0.78 | ESR2 (0.72) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL16047538 | 0.78 | PIM1 (0.38) | ESR2POLBRECQLALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-22 | — | — | US | disclosed |
| EP-3421458-B1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-11 | — | — | EP | disclosed |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-08 | — | — | US | disclosed |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-04 | — | — | US | disclosed |
| US-20190152937-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-23 | — | — | US | disclosed |
| EP-3421458-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | Janssen Pharmaceutica NV (BE) | 2019-01-02 | — | — | EP | disclosed |
| US-10155737-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-18 | — | — | US | disclosed |
| EP-2970157-B1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-25 | — | — | EP | disclosed |
| US-20170088531-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-30 | — | — | US | disclosed |
| US-9562053-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-07 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | GCK, GCKR, HK1 | ESR2 1646/4885CA12 3102/4885CA1 1547/4885 |
| US-10155737-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | ESR2 99/4885CA12 4456/4885CA1 4805/4885 |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | ESR2 99/4885CA12 4456/4885CA1 4805/4885 |
| US-20190152937-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | ESR2 99/4885CA12 4456/4885CA1 4805/4885 |
| US-20170088531-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | ESR2 99/4885CA12 4456/4885CA1 4805/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | ESR2 1646/4885CA12 3102/4885CA1 1547/4885 |
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | ESR2 99/4885CA12 4456/4885CA1 4805/4885 |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | ESR2 99/4885CA12 4456/4885CA1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.